Show me a biotech CEO that is not talking about deals. It's a load of crock, most are way too early. Why is Campbell any different? Just got a hunch? I invest almost exclusively in biotech companies and I am happy to be sceptical about what the Companies I invest in and what they are saying, because they all pump the same lines - high unmet medical need, best in class, partnerships etc etc.
Reality is that a deal is much more likely further down the track than after GMP.
Ann: Presentation to highlight broader potential of Deoxymabs, page-69
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $3.172K | 453.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 3529290 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1082143 | 8 |
View Market Depth
| Last trade - 10.50am 18/06/2024 (20 minute delay) ? |
| PAB (ASX) Chart |